5 completed. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
Follow Dyslipidaemias: new trials by email Literature Review of Dyslipidaemias trials Research Report on Dyslipidaemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs. an undetermined dose of GSK1292263, ascending dose of GSK1292263 - Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 76 | 2008-09-04 | 2017-07-07 |
| Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects GSK256073 - Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 30 | 2008-05-12 | 2017-06-05 |
| A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers GSK256073A tablets + IR niacin tablets - Healthy Subjects, Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 24 | 2007-12-01 | 2012-04-30 |
| A Second Study to Determine the Effect of GSK256073A on HVTs GSK256073A tablets - Healthy Subjects, Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 4 | 2007-10-01 | 2012-06-04 |
| Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers GSK256073A tablets - Healthy Subjects, Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 56 | 2007-06-01 | 2012-06-04 |
Flushing (1)
Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Skin Manifestations (1)
8-chloro-3-pentyl-1H-purine-2,6(3H,7H)-dione (1)
GlaxoSmithKline (5)
United States (5)